Governance and RemunerationRemuneration ReportRemuneration Report 2022
Remuneration Report 2022
This Remuneration Report describes PolyPeptide’s remuneration governance and principles, structure and elements. We have prepared this report in compliance with the requirements of the Swiss Ordinance against Excessive Compensation with respect to Listed Stock Corporations (“OaEC”)1, Polypeptide Group’s Articles of Association as well as the SIX Swiss Exchange Directive on Information relating to Corporate Governance (“DCG”) and the principles of the Swiss Code of Best Practice for Corporate Governance issued by economiesuisse.2
All information within this Remuneration Report 2022 refers to the Company’s organization, Articles of Association3 and Organizational Regulations4 that were in effect as of 31 December 2022 (unless otherwise stated).5
1As part of the reform of Swiss corporate law, the provisions on compensation from the OaEC were incorporated into the Swiss Code of Obligations (“CO”) with effect as of 1 January 2023, and the OaEC was repealed as of the same date. For the year ended 31 December 2022, the OaEC remained in force.
2In its version as approved by the board of economiesuisse on 28 August 2014.
5In line with the new regulations arising from the reform of Swiss corporate law, PolyPeptide Group AG (the “Company”) will propose conforming amendments to its Articles of Association at the upcoming AGM 2023, such amendments to be set out in the invitation and agenda. Thereafter, the Board of Directors plans to amend relevant other regulations of the Company, in particular the Company’s Organizational Regulations. For certain remuneration related regulations, we have included explanatory footnotes herein.